Boston Trust Walden Corp Sells 6,866 Shares of Waters Corporation $WAT

Boston Trust Walden Corp reduced its holdings in shares of Waters Corporation (NYSE:WAT) by 6.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 105,541 shares of the medical instruments supplier’s stock after selling 6,866 shares during the period. Boston Trust Walden Corp owned about 0.11% of Waters worth $31,430,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in WAT. SG Americas Securities LLC lifted its position in Waters by 543.8% during the 4th quarter. SG Americas Securities LLC now owns 37,244 shares of the medical instruments supplier’s stock valued at $14,146,000 after acquiring an additional 31,459 shares during the period. Mackenzie Financial Corp lifted its holdings in shares of Waters by 12.2% during the third quarter. Mackenzie Financial Corp now owns 231,852 shares of the medical instruments supplier’s stock valued at $69,512,000 after purchasing an additional 25,182 shares during the last quarter. Banque Cantonale Vaudoise boosted its position in shares of Waters by 329.0% in the 4th quarter. Banque Cantonale Vaudoise now owns 4,294 shares of the medical instruments supplier’s stock worth $1,631,000 after purchasing an additional 3,293 shares in the last quarter. Nordea Investment Management AB increased its position in Waters by 15.8% during the 4th quarter. Nordea Investment Management AB now owns 13,550 shares of the medical instruments supplier’s stock valued at $5,177,000 after buying an additional 1,848 shares in the last quarter. Finally, Graybill Wealth Management LTD. bought a new stake in Waters in the third quarter worth $2,591,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Waters Trading Down 0.2%

WAT opened at $378.62 on Friday. Waters Corporation has a 12 month low of $275.05 and a 12 month high of $414.15. The company has a current ratio of 1.79, a quick ratio of 1.13 and a debt-to-equity ratio of 0.32. The stock has a 50-day moving average of $351.53 and a 200 day moving average of $347.02. The firm has a market cap of $37.18 billion, a P/E ratio of 48.11, a P/E/G ratio of 2.29 and a beta of 1.20.

Waters (NYSE:WAT) last posted its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.31 by $0.39. Waters had a net margin of 11.91% and a return on equity of 15.60%. The company had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same period in the prior year, the company posted $2.25 EPS. The firm’s revenue for the quarter was up 91.4% on a year-over-year basis. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. As a group, research analysts forecast that Waters Corporation will post 14.51 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on WAT. Wells Fargo & Company increased their price objective on shares of Waters from $355.00 to $370.00 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Barclays increased their price target on shares of Waters from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Wolfe Research assumed coverage on Waters in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $425.00 price objective on the stock. Sanford C. Bernstein assumed coverage on Waters in a report on Friday, June 26th. They issued an “outperform” rating and a $435.00 price objective for the company. Finally, Robert W. Baird set a $387.00 target price on Waters in a research report on Wednesday, May 6th. Four analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, Waters has an average rating of “Moderate Buy” and a consensus price target of $396.68.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.